Journal for ImmunoTherapy of Cancer
Open Access Publication
Rights and Permissions
Schaettler MO, Desai R, Wang AZ, et alTCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastomaJournal for ImmunoTherapy of Cancer 2023;11:e006121. doi: 10.1136/jitc-2022-006121 © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Schaettler, Maximilian O.; Desai, Rupen; Wang, Anthony Z.; Livingstone, Alexandra J.; Kobayashi, Dale K.; Coxon, Andrew T.; Bowman-Kirigin, Jay A.; Liu, Connor J.; Li, Mao; Bender, Diane E.; White, Michael J.; Kranz, David M.; Johanns, Tanner M.; and Dunn, Gavin P., "TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma." Journal for ImmunoTherapy of Cancer. 11, 2. e006121 (2023).
ICTS (Institute of Clinical and Translational Sciences)